Roche responds to the 'Herceptin or deception' article.
Petersen
Svend
S
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D004341:Drug Evaluation / Q000379:methods; D004335:Drug and Narcotic Control; D005260:Female; D006801:Humans; D009520:New Zealand; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab